Clinical Trial Update: A Study to Evaluate the Effects of Efalizumab on Immune Responses in Subjects With Moderate Plaque Psoriasis [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the effects of efalizumab on immune responses in adults with moderate plaque psoriasis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• Efalizumab (efalizumab)

Snippet

Sponsor: Genentech, Inc. | Conditions: Plaque Psoriasis | Phase 1 | Status: COMPLETED